Omeprazole - Generic Drug Details

What are the generic drug sources for omeprazole and what is the scope of patent protection?

Omeprazole is the generic ingredient in eight branded drugs marketed by Actavis Labs Fl Inc, Apotex, Aurobindo Pharma, Breckenridge, Dr Reddys Labs Ltd, Glenmark Pharms Ltd, Hetero Labs Ltd Iii, Impax Labs, Lannett Co Inc, Lupin, Pharmobedient, Sandoz, Strides Pharma, Teva Pharms Usa, Xiromed, Zydus Pharms Usa Inc, Astrazeneca, Dexcel Pharma, Dr Reddys, Sun Pharm, Dexcel, Aurobindo Pharma Ltd, Spil, Azurity, Marksans Pharma, P And L, Perrigo R And D, Ajanta Pharma Ltd, Anda Repository, Aurolife Pharma Llc, Chartwell Rx, Sciegen Pharms, Strides Pharma Intl, Zydus, Zydus Pharms, Salix, Riley Consumer, and Novitium Pharma, and is included in fifty-six NDAs. There are eleven patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Omeprazole has nine patent family members in six countries.

There are one hundred and thirty-one drug master file entries for omeprazole. Ninety-three suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for omeprazole

International Patents:	9
US Patents:	11
Tradenames:	8
Applicants:	38
NDAs:	56
Drug Master File Entries:	131
Finished Product Suppliers / Packagers:	93
Raw Ingredient (Bulk) Api Vendors:	144
Clinical Trials:	493
Patent Applications:	7,082
Drug Prices:	Drug price trends for omeprazole
Drug Sales Revenues:	Drug sales revenues for omeprazole
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for omeprazole
What excipients (inactive ingredients) are in omeprazole?	omeprazole excipients list
DailyMed Link:	omeprazole at DailyMed

See drug prices for omeprazole

See drug sales revenues for omeprazole

Recent Clinical Trials for omeprazole

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Shandong Suncadia Medicine Co., Ltd.	PHASE1
Rehman Medical Institute - RMI	PHASE4
Tanta University	PHASE3

See all omeprazole clinical trials

Generic filers with tentative approvals for OMEPRAZOLE

Applicant	Application No.	Strength	Dosage Form
		40MG	CAPSULE, DELAYED REL PELLETS;ORAL
		20MG	CAPSULE, DELAYED REL PELLETS;ORAL
		10MG	CAPSULE, DELAYED REL PELLETS;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for omeprazole

Drug Class	Proton Pump Inhibitor
Mechanism of Action	Cytochrome P450 2C19 Inhibitors Proton Pump Inhibitors

Medical Subject Heading (MeSH) Categories for omeprazole

Anti-Ulcer Agents

Proton Pump Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for omeprazole

A02BC	Proton pump inhibitors
A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
A02	DRUGS FOR ACID RELATED DISORDERS
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for OMEPRAZOLE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OMEPRAZOLE	Delayed-release Tablets	omeprazole	20 mg	022032	1	2015-06-03

US Patents and Regulatory Information for omeprazole

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Spil	OMEPRAZOLE MAGNESIUM	omeprazole magnesium	CAPSULE, DELAYED RELEASE;ORAL	210593-001	Jul 20, 2018		DISCN	No	No
Strides Pharma Intl	OMEPRAZOLE AND SODIUM BICARBONATE	omeprazole; sodium bicarbonate	CAPSULE;ORAL	078966-002	May 25, 2010		DISCN	No	No
Astrazeneca	PRILOSEC	omeprazole	CAPSULE, DELAYED REL PELLETS;ORAL	019810-002	Jan 15, 1998		DISCN	Yes	No
Apotex	OMEPRAZOLE	omeprazole	TABLET, DELAYED RELEASE;ORAL	210070-001	Feb 11, 2019		DISCN	No	No
Sciegen Pharms	OMEPRAZOLE AND SODIUM BICARBONATE	omeprazole; sodium bicarbonate	CAPSULE;ORAL	207476-001	Dec 6, 2016	AB	RX	No	No
Dr Reddys Labs Ltd	OMEPRAZOLE MAGNESIUM	omeprazole magnesium	CAPSULE, DELAYED RELEASE;ORAL	078878-001	Jun 5, 2009		OTC	No	Yes
Hetero Labs Ltd Iii	OMEPRAZOLE MAGNESIUM	omeprazole magnesium	TABLET, DELAYED RELEASE;ORAL	211732-001	Mar 25, 2020		OTC	No	No

Expired US Patents for omeprazole

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Dexcel Pharma	OMEPRAZOLE	omeprazole	TABLET, DELAYED RELEASE;ORAL	022032-001	Dec 4, 2007	9,023,391

International Patents for omeprazole

Country	Patent Number	Title	Estimated Expiration
Australia	2017285390	Stable orally disintegrating pharmaceutical compositions
European Patent Office	3471708	COMPOSITIONS PHARMACEUTIQUES STABLES À DÉSINTÉGRATION ORALE (STABLE ORALLY DISINTEGRATING PHARMACEUTICAL COMPOSITIONS)
European Patent Office	3932396	COMPOSITIONS PHARMACEUTIQUES STABLES À DÉSINTÉGRATION ORALE (STABLE ORALLY DISINTEGRATING PHARMACEUTICAL COMPOSITIONS)
World Intellectual Property Organization (WIPO)	2017216789
European Patent Office	2293782	FORMULE STABLE DE BENZIMIDAZOLE (STABLE BENZIMIDAZOLE FORMULATION)
Spain	2552723
Hong Kong	1156209	穩定的苯並咪唑製劑 (STABLE BENZIMIDAZOLE FORMULATION)

Supplementary Protection Certificates for omeprazole

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0984957	SPC/GB11/013	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
0984957	2012/048	Ireland		PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812
1411900	2011/016	Ireland		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
1411900	SPC/GB11/015	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
0124495	SPC/GB01/006	United Kingdom		PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727
1411900	2011C/016	Belgium		PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214

Omeprazole Market Dynamics and Financial Trajectory: Exclusivity, Competition, Pricing, and Revenue Outlook

Last updated: June 25, 2026

Omeprazole is a mature, off-patent proton pump inhibitor (PPI) with global availability of multiple low-cost generics. Competitive pricing pressure, long-standing payer familiarity, and broad substitution have kept revenue growth modest and mostly tied to volume, pack migration, and channel mix rather than patent-led durability. Financial trajectory is characterized by declining brand-led sales, stable-to-soft generics pricing, and periodic market reconfiguration driven by supply, regulatory actions, and formulation shifts (oral delayed-release, OTC switches, and select combination products).

What is omeprazole’s market size and revenue trajectory by year?

Featured snippet: Omeprazole revenues track global PPI volume and generic price erosion rather than stepwise innovation cycles, with most growth coming from unit demand and mix changes rather than premium pricing.

Omeprazole market dynamics are shaped by four forces:

1. Patent cliff already passed across major markets, with the active ingredient widely generic and interchangeable.
2. Payer behavior supports substitution within PPIs, often favoring the lowest net-cost option.
3. Pricing compression is structural, driven by multi-source generic competition and tendering.
4. Formulation and package-level economics determine share within class (strengths, dosing frequency, and OTC vs prescription channels).

Financial trajectory pattern (typical for mature APIs like omeprazole)

• Early period: brand-driven growth (historical)
• Middle period: mix shift to generics
• Current period: stable demand but shrinking price per unit, plus intermittent spikes from supply disruptions or procurement cycles

How do patent expirations and generic entry affect omeprazole pricing and sales?

Featured snippet: Omeprazole’s active ingredient is off-patent, so generic entry has already reset the market to multi-source competition, with ongoing changes driven by supply and formulary tendering.

Because omeprazole is a widely genericized product, the market has already experienced:

• Initial generic launches that drove steep declines from brand pricing
• Subsequent re-tendering that further compressed net prices
• Ongoing competitive intensity as additional manufacturers enter and win share in procurement markets

What this means commercially

• Brand revenue trajectories are not governed by new exclusivity but by defensive marketing, line extensions, and channel positioning.
• Generic producers compete largely on cost of goods, manufacturing continuity, logistics, and bid strategy.
• Specialty-like “life-cycle” strategies are limited; most incremental gains are in packaging and compliance-driven dosing convenience.

What patents protect omeprazole and how strong is the patent estate today?

Featured snippet: For omeprazole itself, the patent estate is generally not a basis for lasting exclusivity because key active-ingredient and core composition protection has expired.

For business planning, the practical question is not whether patents exist historically, but whether any current assets create enforceable barriers against generic substitution of omeprazole oral delayed-release products.

Current-world reality

• The API is standard.
• Competitive differentiation in most markets is not blocked by omeprazole molecule patents.
• Remaining protection, if any, tends to be product-specific (e.g., particular formulation, combination, or manufacturing method) rather than the active ingredient itself.

Commercial impact of weak active-ingredient exclusivity

• Pricing is governed by tender outcomes and multi-source dynamics.
• Brand margins depend on rebates and trade terms rather than exclusivity leverage.

What formulations are protected for omeprazole (and what does that mean for competitors)?

Featured snippet: Protection, where it exists, is most likely tied to specific formulations, dose forms, or combinations rather than omeprazole’s core chemical entity.

Common commercially relevant product categories include:

• Omeprazole delayed-release capsules/tablets (primary generic base)
• Higher-concentration strengths (pack and dosing convenience)
• OTC vs Rx presentations (regulatory status affects channel and marketing strategy)
• Combination products (where device, fixed-dose synergy, or added components can create distinct IP and regulatory routes)

Barrier type that matters

• If a competitor’s path requires a distinct formulation or combination component not covered by existing product-specific patents, that can affect launch timing.
• If no enforceable formulation patents remain, entry timing is mostly regulatory and supply-driven.

When does omeprazole lose exclusivity or exclusivity-by-product for specific markets?

Featured snippet: Omeprazole active-ingredient exclusivity has largely expired; remaining “exclusivity” dynamics are product- and territory-specific and usually revolve around formulation/combo assets or regulatory data protections rather than new molecule protection.

In practice, the market does not behave like a single global exclusivity clock because:

• OTC switches and formulation approvals differ by country.
• Combination products can carry separate regulatory pathways and potential exclusivity.
• Manufacturing changes can trigger regulatory renewals or life-cycle variations without creating durable patent blocks.

What is the Orange Book status of omeprazole products?

Featured snippet: Omeprazole is widely represented on FDA drug listings, and most listed products are generics or legacy references whose key patents have expired; any “Orange Book” protection that remains is typically limited to specific product patents rather than the core API.

Orange Book status is a product-by-product question:

• Each NDC maps to a reference listed drug (RLD) and associated patents.
• Patent listings may differ across strengths, dosage forms, and manufacturers.
• For market-entry risk, the relevant point is whether unexpired patents cover the proposed ANDA label and whether they are subject to Paragraph IV challenges.

What Paragraph IV challenges have been filed for omeprazole?

Featured snippet: Paragraph IV challenges are typically less informative for omeprazole now because the market is already populated with multiple generics; later-stage disputes are more likely to involve product-specific patents or specific NDCs.

Commercially, the key insight is:

• If multiple ANDAs already exist, new entries tend to be priced into the lowest net-cost bands.
• Litigation may affect individual products or specific filings, but rarely reverts the whole class to brand-like pricing.

What generic entry risks exist for omeprazole in the US, EU, and key LATAM markets?

Featured snippet: Generic entry risk is low for the active ingredient because most markets already have multi-source competition; the higher risk is supply and compliance rather than patent-driven delays.

US risk profile

• Delays more likely relate to manufacturing capacity, inspections, labeling transitions, and supply chain continuity than to successful patent enforcement.
• New entrants mostly add capacity and compete on price and contract performance.

EU risk profile

• Substitution rules and tendering can drive fast share changes.
• National pricing and reimbursement decisions can swing unit demand.

LATAM risk profile

• Regulatory approval and local tender cycles often dominate.
• Price is highly sensitive to wholesale and payer reimbursement adjustments.

How does omeprazole compare with other PPIs on competitive intensity and financial performance?

Featured snippet: Omeprazole faces high competitive intensity similar to other first-generation PPIs, but it benefits from deep formulary penetration and long generic track history.

Relative dynamics across PPIs:

• Esomeprazole and pantoprazole also have large generic ecosystems.
• Rabeprazole and lansoprazole vary by territory and tender cycles.
• Omeprazole’s advantage is scale and broad interchangeability as a class standard.

Business implication

• PPIs behave like a commodity segment once generics saturate.
• Brand differentiated outcomes depend on patient support programs, contracting terms, and specific combination/strength strategies, not molecule exclusivity.

Which companies dominate omeprazole supply and how does that shape market pricing?

Featured snippet: Omeprazole is supplied by many manufacturers; price outcomes are driven by how efficiently large generic players bid into tenders and maintain manufacturing reliability.

Market pricing behavior is consistent with:

• Bid-based procurement for public and large private payers.
• Channel-specific contracts for wholesalers and pharmacy chains.
• Risk premiums during supply tightness that can temporarily lift net prices and distributor margins.

What factors drive omeprazole price and margin (tenders, reimbursement, OTC, and supply)?

Featured snippet: Omeprazole price is primarily determined by reimbursement policy, tender outcomes, and generic supply conditions rather than by patent status.

Key drivers:

1. Reimbursement tiers and reference pricing: compresses net price across categories.
2. Gross-to-net dynamics: rebates and discounts reshape realized price.
3. OTC channel expansion: can shift volume away from prescription and stabilize some utilization.
4. API and manufacturing cost cycles: affects supply pricing and margin availability.
5. Quality and inspection outcomes: can force temporary supply constraints and price resets.

How do safety and label considerations affect omeprazole market uptake?

Featured snippet: Safety profile and long-term use considerations shape prescribing and payer management but generally do not create a new competitive barrier in an already-generic market.

Commercial effects show up as:

• Guideline-based utilization management: PPIs are often recommended with risk-based duration.
• Payer utilization controls: step edits or prior authorization in certain settings.
• Switching within class: adverse label shifts rarely end PPI use; they shift selection between molecules.

What litigation or settlements materially affect omeprazole economics?

Featured snippet: Broad omeprazole class pricing is not typically driven by litigation, but settlements tied to specific NDCs can influence short-term market shares.

In a multi-source market:

• Litigation outcomes are most relevant to individual product launches and specific formulation/label variants.
• Even when disputes delay one filing, overall category supply can continue through existing generics.

What are the regulatory milestones and FDA status implications for omeprazole?

Featured snippet: Regulatory status primarily affects labeling, interchangeability, and competition among generics rather than creating new exclusivity.

Operational milestones:

• ANDA approvals enable generic distribution.
• Labeling alignment (indications, dosage forms, and warnings) affects substitution at the pharmacy counter.
• OTC transitions affect channel mix.

Key takeaways: what the market dynamics imply for forecasting and investment

1. Omeprazole is a commodity-style pharmaceutical with revenue and market share driven by volume, contracting, and price erosion, not by active-ingredient exclusivity.
2. Patent leverage is limited commercially today; product-specific formulation and combination protections are the more realistic sources of any remaining differentiation.
3. Financial trajectory is stable utilization with falling price until new competitive dynamics (supply constraints, tender resets, or combination launches) change net economics.
4. Competitive intensity stays high because multi-source generic supply is structurally easy to expand relative to new-molecule development.
5. Best predictors of realized margin are contracting and supply reliability, not patent estate strength.

FAQs

1) Is omeprazole still protected by any US patents that block generics?
Omeprazole’s core molecule protection is largely expired; any remaining blocking effect would be tied to specific unexpired product patents listed against particular FDA RLD/NDC combinations.

2) Do new omeprazole formulations create meaningful exclusivity or price premiums?
Price premiums are unlikely in the absence of enforceable exclusivity, but formulation changes can shift mix and contracting categories.

3) How do OTC omeprazole products change market revenue compared with prescription?
OTC channels can stabilize demand and change distribution economics, shifting revenue away from payer rebates toward consumer retail economics.

4) What supply events most affect omeprazole pricing?
Manufacturing downtime, quality/inspection actions, and API supply constraints that reduce available inventory tend to create the biggest short-term price movement.

5) How should investors assess competitive risk for omeprazole producers?
Focus on bid competition, realized net pricing trends, manufacturing capacity, and quality track record rather than patent litigation as the primary driver.

---

References (APA)

No sources were cited.